LGND · Ligand Pharmaceuticals Inc
$288.01
-8.27 (-2.79%)
At close · Jul 29
Market Cap
$5.94B
Shares
20.04M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-14 | — | |
| 8-K | 2026-06-25 | — | |
| 8-K | 2026-06-22 | — | |
| 8-K | 2026-06-09 | 2026-06-05 | |
| 8-K | 2026-05-18 | 2026-05-16 | |
| 10-Q | 2026-05-08 | 2026-03-31 | |
| 8-K | 2026-05-07 | — | |
| 8-K | 2026-04-30 | 2026-04-24 | |
| 8-K | 2026-04-27 | — | |
| DEF 14A | 2026-04-21 | 2025-12-31 | |
| 10-K | 2026-02-27 | 2025-12-31 | |
| 8-K | 2026-02-26 | — | |
| 8-K | 2025-12-18 | — | |
| 10-Q | 2025-11-07 | 2025-09-30 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-09-16 | 2025-09-12 | |
| 8-K | 2025-08-14 | 2025-08-11 | |
| 8-K | 2025-08-11 | — | |
| 10-Q | 2025-08-08 | 2025-06-30 | |
| 8-K | 2025-08-07 | — | |
| 8-K | 2025-07-02 | — | |
| 8-K | 2025-06-09 | — | |
| 10-Q | 2025-05-09 | 2025-03-31 | |
| 8-K | 2025-05-08 | — | |
| DEF 14A | 2025-04-22 | 2024-12-31 | |
| 8-K | 2025-04-17 | 2025-04-16 | |
| 10-K | 2025-02-28 | 2024-12-31 | |
| 8-K | 2025-02-27 | — | |
| 8-K | 2025-02-25 | 2025-02-24 | |
| 10-Q | 2024-11-08 | 2024-09-30 | |
| 8-K | 2024-11-07 | — | |
| 10-Q | 2024-08-07 | 2024-06-30 | |
| 8-K | 2024-08-06 | — | |
| 8-K | 2024-08-02 | — | |
| 8-K | 2024-07-17 | 2024-07-15 | |
| 8-K | 2024-07-10 | 2024-07-08 | |
| 8-K | 2024-07-08 | — | |
| 8-K | 2024-06-27 | — | |
| 8-K | 2024-06-18 | — | |
| 8-K | 2024-06-17 | 2024-06-14 | |
| 8-K | 2024-05-30 | 2024-05-29 | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-07 | — | |
| 8-K | 2024-05-07 | 2024-05-06 | |
| DEF 14A | 2024-04-25 | 2023-12-31 | |
| 8-K | 2024-04-19 | 2024-04-17 | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2024-02-27 | — | |
| 8-K | 2024-01-08 | 2024-01-05 | |
| 8-K | 2023-12-01 | 2023-11-29 |
Showing 1–50 of 130 filings
Key facts
CIK
886163
CUSIP
53220K504
13F (30d)
117 filings
114 filers
Visit website
Investor relations